SCHEMBL422824

SCHEMBL422824

O=C(O)c1cc(I)cc(I)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPMT P51580 5/20 0.59
CA12 O43570 3/20 0.50
CA1 P00915 3/20 0.50
CA2 P00918 3/20 0.50
CA7 P43166 3/20 0.50
CA9 Q16790 3/20 0.50
CA14 Q9ULX7 3/20 0.50
TP53 P04637 2/20 0.48
CA3 P07451 2/20 0.48
CA4 P22748 2/20 0.48
CA6 P23280 2/20 0.48
CA5A P35218 2/20 0.48
CA5B Q9Y2D0 2/20 0.48
KDM4E B2RXH2 1/20 0.48
ALDH1A1 P00352 1/20 0.48
LMNA P02545 1/20 0.48
MAPT P10636 1/20 0.48
SELL P14151 1/20 0.48
HPGD P15428 1/20 0.48
SELP P16109 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1951073 0.94 TPMT (0.59) TPMTCA12CA1CA2CA7
SCHEMBL9988254 0.85 CA12 (0.68) TPMTCA12CA1CA2CA7
SCHEMBL4757914 0.83 TPMT (0.70) TPMTCA12CA1CA2CA7
SCHEMBL29528960 0.83 TPMT (0.48) TPMTCA12CA1CA2CA7
SCHEMBL200827 0.83 TPMT (0.48) TPMTCA12CA1CA2CA7
SCHEMBL10799482 0.83 TPMT (0.48) TPMTCA12CA1CA2CA7
SCHEMBL12837657 0.83 TPMT (0.48) TPMTCA12CA1CA2CA7
SCHEMBL7947897 0.83 DHODH (0.55) TPMTCA12CA1CA2CA7
SCHEMBL1947967 0.83 HCAR1 (0.59) TPMTCA12CA1CA2CA7
SCHEMBL16925558 0.83 TPMT (0.70) TPMTCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116440315-A Multi-mode developed gelatin sponge microsphere and preparation method thereof 海南百迈科医疗科技股份有限公司 2023-07-18 CN claimed
CN-115487342-A Self-developing absorbable embolism microsphere and preparation method thereof 海南百迈科医疗科技股份有限公司 2022-12-20 CN claimed
CN-113995884-A Liquid embolic agent and preparation method thereof 苏州浩微生物医疗科技有限公司 2022-02-01 CN claimed
CN-106822983-B Developable embolism microsphere for treating tumor diseases by minimally invasive intervention therapy and preparation method thereof 苏州恒瑞迦俐生生物医药科技有限公司 2020-09-15 CN claimed
US-9433501-B2 Inflation media for implants DIRECT FLOW MEDICAL, INC. (US) 2016-09-06 US claimed
EP-2571561-A2 INFLATION MEDIA FOR IMPLANTS Direct Flow Medical, Inc. (US) 2013-03-27 EP claimed
US-20120022629-A1 INFLATION MEDIA FOR IMPLANTS DIRECT FLOW MEDICAL, INC. (US) 2012-01-26 US claimed
WO-2011146759-A2 INFLATION MEDIA FOR IMPLANTS DIRECT FLOW MEDICAL, INC. (US) 2011-11-24 WO claimed
US-20090203877-A1 X-RAY-DENSE CONJUGATE EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINKUM 2009-08-13 US claimed
EP-2046392-A2 RADIODENSE CONJUGATE Eberhard-Karls-Universität Tübingen Universitätsklinikum (DE) 2009-04-15 EP claimed
WO-2008012102-A2 RADIODENSE CONJUGATE EBERHARD-KARLS-UNIVERSITAET TUEBINGEN UNIVERSITAETSKLINIKUM (DE) 2008-01-31 WO claimed
CN-1284773-C Ortho-pyridinequinone derivative, composite containing said derivative, its preparation method and application BAIRUI GLOBAL CO LTD (VG) 2006-11-15 CN claimed
CN-1477099-A O-pyridinoquinone derivative, composition containing the same, preparation method and use of the same 百瑞全球有限公司 2004-02-25 CN claimed
CN-122029155-A Heterocyclic compound and harmful arthropod control composition containing same 住友化学株式会社 2026-05-12 CN disclosed
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS BOSTON SCIENTIFIC SCIMED, INC. (US) 2026-04-30 US disclosed
US-12610949-B2 Heteroaryl-triazole compounds as pesticides BAYER AKTIENGESELLSCHAFT (DE) 2026-04-28 US disclosed
US-4563465-A ANTISEROTONINE AGENTS MERRELL DOW PHARMACEUTICALS INC. (US) 1986-01-07 US disclosed
US-4486441-A PROPHYLAXIS MERRELL TORAUDE ET COMPAGNIE (FR) 1984-12-04 US disclosed
EP-0111608-A1 Pseudotropyl halogeno-benzoates and their use in migraine treatment MERRELL TORAUDE ET COMPAGNIE (FR) 1984-06-27 EP disclosed
EP-0067770-A2 Treatment of migraine with tropyl benzoate derivatives MERRELL DOW FRANCE ET CIE (FR) 1982-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12610949-B2 Heteroaryl-triazole compounds as pesticides CTRL, PTMS, DDT TPMT 1299/4885CA12 4183/4885CA1 3529/4885
US-20090203877-A1 X-RAY-DENSE CONJUGATE FCGR3B, KLK3, XPA TPMT 2515/4885CA12 140/4885CA1 1247/4885
US-20260115330-A1 RADIOPAQUE MULTI-ARM POLYMERS FOR MEDICAL APPLICATIONS KLK3, BRDT, BPHL TPMT 4080/4885CA12 233/4885CA1 390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.